BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-156@catalystbrief.girapphe.com
DTSTAMP:20261118T181559Z
LAST-MODIFIED:20261118T181559Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Readout: Janssen-Cilag Ltd. — Guselkumab [Mar 2027]
DESCRIPTION:Phase 3 primary completion: A Study of Guselkumab in Participan
 ts With Fistulizing\, Perianal Crohn's Disease.\nSource: https://clinicalt
 rials.gov/study/NCT05347095\nhttps://catalystbrief.girapphe.com/e/156?lang
 =en\nNot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/156?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
